Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Innovation Council · Running

fight-dm1 First In class oliGo THerapy for Myotonic Dystrophy type 1 (DM1)

Coordinator
Arthex Biotech SL, Spain
Runs
1 January 2023 to 30 June 2025
Status
Running
EU funding
€2.5m
Total cost
€20.1m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190181217

What the project is doing

In the project's own words, from its summary on CORDIS.

Myotonic dystrophy type 1 (DM1) is a clinically and genetically heterogeneous disorder with more than 1 million diagnosed patients worldwide, making it the most common adult muscular dystrophy. Available treatments only relief symptoms. Given this need, we offer ATX-01, a first in class miRNA therapy that inhibits miR-23b without changing the DNA, which rescues DM1 pathogenic mis-splicing. We have demonstrated improved target engagement effects in skeletal and respiratory muscle in in-vitro and in-vivo studies, granting us an FDA pre-IND approval and orphan drug designation.

Our approach, antimiRs conjugated to fatty acids, constitutes the ENTRY platform, which guarantees efficient drug delivery to target muscular and extra-muscular tissue at low doses. This patented technology will be validated through a Phase I/IIa clinical trial and chronic preclinical studies, to then be extended to applications as other myotonic dystrophies, Fuchs dystrophy, cachexia, among other opportunities.

Topics

Who is involved

OrganisationCityCountryRole
Arthex Biotech SLValenciaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI